Blog

Senators Expand Probe of Pfizer and Eli Lilly’s Telehealth Partnerships In an ongoing effort to scrutinize the direct-to-consumer (DTC) telehealth platforms of major pharmaceutical companies Pfizer and Eli Lilly, a group of U.S. senators has broadened its investigation to include telehealth provider partners. The focus lies on the potential influence these partnerships may have on…

Roche Overhauls Spark Therapeutics, Records $2.4B Full Impairment In a move that highlights the challenges facing the gene therapy sector, Roche has announced a “fundamental reorganization” of Spark Therapeutics, the gene therapy unit it acquired for $4.3 billion in 2019. This shift, part of Roche’s broader strategy to revamp its pharmaceutical division, has resulted in…

Viking Therapeutics’ New Manufacturing Contract: A Game Changer for Weight-Loss Drug VK2735 Introduction Viking Therapeutics Inc. (VKTX) recently made headlines when its stock surged by 8% following the announcement of a significant manufacturing agreement with CordenPharma, a private Swiss company. This partnership marks a pivotal moment for Viking, particularly concerning its promising oral obesity drug…

A Once-Yearly PrEP? Gilead’s Lenacapavir Shows Promise as Company Plots Phase 3 Gilead Sciences has captured significant attention in the healthcare sector with its latest advancements in HIV prevention. The company’s investigational drug, lenacapavir, has shown remarkable potential as a once-yearly preexposure prophylaxis (PrEP) treatment option for HIV, following impressive clinical results for its twice-yearly…

Ozempic’s New Frontier: The War on Aging For decades, scientists have searched for a drug capable of slowing aging. Emerging research suggests that the answer may lie in GLP-1s, a class of diabetes and weight-loss medications, including popular brands like Ozempic and Wegovy. Recent studies indicate these drugs offer health benefits that extend beyond their…

With Blood and Growth Disorder Bids Panning Out, Novo Nordisk Plots Path to Rare Disease Leadership Novo Nordisk has been a significant player in the field of rare diseases for over 45 years. However, this sector has often taken a back seat to the company’s more mainstream endeavors in treating diabetes and other chronic conditions….

In Patent Clash Over Injectable Keytruda, Merck and Halozyme Dig In for a Fight In a significant development in the pharmaceutical industry, Merck & Co. and Halozyme Therapeutics are embroiled in a fierce patent dispute concerning an under-the-skin version of Merck’s blockbuster cancer drug Keytruda. The legal skirmish underscores the high stakes involved in drug…

Novo Nordisk Launches NovoCare Pharmacy to Combat Cheaper Compounded Versions of Wegovy Novo Nordisk is taking proactive measures to confront the growing threat posed by compounding pharmacies that have been producing cheaper versions of its popular obesity medication, Wegovy (semaglutide). The Danish pharmaceutical giant has introduced NovoCare Pharmacy, which provides direct home shipping of Wegovy…

The Importance of Real-World Evidence in HIV Treatment Witnessing the devastation caused by the HIV epidemic in the 1980s through my father’s dedication to helping those affected by the virus had a profound effect on my life. His unwavering compassion for individuals living with HIV inspired me to follow in his footsteps and pursue a…

Roche Gains FDA Approval for TNKase: A Significant Advancement in Stroke Treatment In a groundbreaking development for stroke treatment, Roche’s subsidiary, Genentech, has received FDA approval for TNKase (tenecteplase), marking it as the second FDA-approved medication for acute ischemic stroke (AIS). This approval expands Roche’s portfolio within the urgent care landscape, where Genentech has maintained…